ABSTRACT
Danirixin (GSK1325756) is a small, high-affinity, selective and reversible CXCR2 antagonist in development for treatment of chronic obstructive pulmonary disease. The objective of the study was to evaluate the relative bioavailability, including the inter-subject variability, of a conventional immediate-release (IR) formulation and two prototype bioenhanced formulations of danirixin during gastric acid suppression in a healthy, elderly population. A single-centre, crossover study in healthy male and female volunteers aged 65-80 years was conducted. Subjects were randomised to receive danirixin 50 mg IR in the fed and fasted states and danirixin 50 mg Bioenhanced Formulation 1 and 2 in the fasted state. All subjects also received omeprazole 20 mg each morning beginning 4 days prior to the first treatment period and continuing through danirixin dosing in the final treatment period. Twenty subjects were randomised and completed the study. Bioenhanced Formulation 2 in the fasted state demonstrated the highest adjusted geometric means for AUC(0-t), AUC(0-inf), AUC(0-24) and C max. Danirixin IR demonstrated adjusted means that were higher in the fed state compared with the fasted state. For all formulations tested, there was substantial inter-subject variability (CVb >100 % for all formulations). The overall incidences of adverse events (AEs) were 10 % for danirixin IR (both in the fed and fasted states) and 15-20 % for the bioenhanced formulations. The majority of AEs were mild in intensity. There were no serious AEs. Concomitant use of omeprazole resulted in large inter-subject variability in the exposure to danirixin. Bioenhanced formulation strategies could not overcome the effect of omeprazole on exposure and variability between subjects.
Subject(s)
Piperidines/administration & dosage , Piperidines/pharmacokinetics , Respiratory System Agents/administration & dosage , Respiratory System Agents/pharmacokinetics , Sulfones/administration & dosage , Sulfones/pharmacokinetics , Administration, Oral , Age Factors , Aged , Biological Availability , Chemistry, Pharmaceutical , Cross-Over Studies , Drug Interactions , England , Fasting/blood , Female , Healthy Volunteers , Humans , Hydrogen-Ion Concentration , Male , Omeprazole/administration & dosage , Piperidines/adverse effects , Piperidines/blood , Piperidines/chemistry , Postprandial Period , Proton Pump Inhibitors/administration & dosage , Respiratory System Agents/adverse effects , Respiratory System Agents/blood , Respiratory System Agents/chemistry , Solubility , Sulfones/adverse effects , Sulfones/blood , Sulfones/chemistry , TabletsABSTRACT
Synthetic membranes used in Franz diffusion cells for topical formulation quality assessment should provide least resistance to drug diffusion. In this study, the diffusion rates of ibuprofen across thirteen membranes were determined using Franz diffusion cells. Correlation of the membrane thickness, pore size and MWCO with drug fluxes was also made. The drug diffusion results showed that the porous membranes were categorized into high-flux (8-18 mg/cm²/h) and low-flux (0.1-3 mg/cm²/h) membranes. The drug fluxes did not show strong correlations (r² < 0.99) with membrane parameters. Synthetic membranes can give variable drug fluxes, thus investigators should be careful in choosing membrane for formulation quality assessment.
ABSTRACT
Small molecule antagonists of the vanilloid receptor TRPV1 (also known as VR1) are disclosed. Pyrrolidinyl ureas such as 8 and 15 (SB-705498) emerged as lead compounds following optimisation of the previously described urea SB-452533. Pharmacological studies using electrophysiological and FLIPR-Ca2+-based assays showed that compounds such as 8 and 15 were potent antagonists versus the multiple chemical and physical modes of TRPV1 activation (namely capsaicin, acid and noxious heat). Furthermore, 15 possessed suitable developability properties to enable progression of this compound into in vivo studies and subsequently clinical development.